Factory 99% Ticagrelor Powder CAS 274693-27-5 Ticagrelor

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A228
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Ticagrelor
• CAS: 274693-27-5
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 100g
• Function: Improvement of Blood Flow
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

Product Name	Ticagrelor
Appearance	White Powder
CAS NO.	274693-27-5
Molecular Formula	C23H28F2N6O4S
Storage	Keep in a cool, dry, dark location

Ticagrelor is a novel, selective, and reversible P2Y12 receptor antagonist. It is a small-molecule anticoagulant developed by AstraZeneca. Chemically, it has the molecular formula C23H28F2N6O4S and is used primarily as an antiplatelet agent. By inhibiting the ADP-mediated activation and aggregation of platelets, ticagrelor helps reduce the formation of blood clots and, consequently, the risk of cardiovascular events such as myocardial infarction and stroke. It is prescribed for patients with acute coronary syndrome (ACS) or those undergoing percutaneous coronary intervention (PCI) to improve cardiovascular outcomes.

1. Antiplatelet Agent: Ticagrelor is used to prevent blood platelets from clumping together and forming blood clots.
2. Cardiovascular Treatment: It is prescribed for patients with acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI) to reduce the risk of cardiovascular events.
3. Adjuvant Therapy: Often used in combination with aspirin and other cardiovascular medications for enhanced therapeutic effects.

1. Inhibition of Platelet Aggregation: Ticagrelor reversibly binds to the P2Y12 receptor on platelets, inhibiting ADP-mediated platelet activation and aggregation.
2. Reduction of Thrombotic Events: By blocking platelet aggregation, it helps reduce the risk of myocardial infarction, stroke, and other thromboembolic events.
3. Improvement of Blood Flow: By preventing clot formation, ticagrelor facilitates better blood flow through the arteries, supporting cardiovascular health.